Merck KGaA - Asset Resilience Ratio
Merck KGaA (MRK) has an Asset Resilience Ratio of 1.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Merck KGaA short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Merck KGaA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Merck KGaA asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Merck KGaA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Merck KGaA's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €597.00 Million | 1.15% |
| Total Liquid Assets | €597.00 Million | 1.15% |
Asset Resilience Insights
- Limited Liquidity: Merck KGaA maintains only 1.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Merck KGaA Industry Peers by Asset Resilience Ratio
Compare Merck KGaA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Merck KGaA (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Merck KGaA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.15% | €597.00 Million ≈ $697.96 Million |
€52.10 Billion ≈ $60.91 Billion |
+0.06pp |
| 2024-12-31 | 1.08% | €558.00 Million ≈ $652.36 Million |
€51.57 Billion ≈ $60.29 Billion |
+0.61pp |
| 2023-12-31 | 0.48% | €231.00 Million ≈ $270.06 Million |
€48.49 Billion ≈ $56.70 Billion |
-0.03pp |
| 2022-12-31 | 0.50% | €244.00 Million ≈ $285.26 Million |
€48.53 Billion ≈ $56.73 Billion |
+0.26pp |
| 2021-12-31 | 0.25% | €112.00 Million ≈ $130.94 Million |
€45.36 Billion ≈ $53.03 Billion |
+0.18pp |
| 2020-12-31 | 0.07% | €29.00 Million ≈ $33.90 Million |
€41.80 Billion ≈ $48.86 Billion |
+0.00pp |
| 2019-12-31 | 0.07% | €29.00 Million ≈ $33.90 Million |
€43.81 Billion ≈ $51.22 Billion |
+0.04pp |
| 2018-12-31 | 0.02% | €8.00 Million ≈ $9.35 Million |
€36.89 Billion ≈ $43.13 Billion |
-0.08pp |
| 2017-12-31 | 0.10% | €35.00 Million ≈ $40.92 Million |
€35.62 Billion ≈ $41.64 Billion |
-0.01pp |
| 2016-12-31 | 0.11% | €43.00 Million ≈ $50.27 Million |
€38.25 Billion ≈ $44.72 Billion |
-0.39pp |
| 2015-12-31 | 0.50% | €191.40 Million ≈ $223.77 Million |
€38.01 Billion ≈ $44.43 Billion |
-7.79pp |
| 2014-12-31 | 8.29% | €2.16 Billion ≈ $2.52 Billion |
€26.01 Billion ≈ $30.41 Billion |
-3.07pp |
| 2013-12-31 | 11.36% | €2.37 Billion ≈ $2.77 Billion |
€20.82 Billion ≈ $24.34 Billion |
+4.06pp |
| 2012-12-31 | 7.30% | €1.58 Billion ≈ $1.85 Billion |
€21.64 Billion ≈ $25.30 Billion |
+2.25pp |
| 2011-12-31 | 5.05% | €1.12 Billion ≈ $1.31 Billion |
€22.12 Billion ≈ $25.86 Billion |
+4.80pp |
| 2010-12-31 | 0.25% | €55.60 Million ≈ $65.00 Million |
€22.39 Billion ≈ $26.17 Billion |
-8.75pp |
| 2009-12-31 | 8.99% | €1.50 Billion ≈ $1.76 Billion |
€16.71 Billion ≈ $19.54 Billion |
+7.86pp |
| 2008-12-31 | 1.13% | €176.80 Million ≈ $206.70 Million |
€15.64 Billion ≈ $18.29 Billion |
-2.66pp |
| 2007-12-31 | 3.79% | €565.30 Million ≈ $660.90 Million |
€14.92 Billion ≈ $17.45 Billion |
+2.15pp |
| 2006-12-31 | 1.64% | €133.10 Million ≈ $155.61 Million |
€8.10 Billion ≈ $9.47 Billion |
-0.48pp |
| 2005-12-31 | 2.12% | €154.20 Million ≈ $180.28 Million |
€7.28 Billion ≈ $8.51 Billion |
-- |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for re… Read more